TY - JOUR
T1 - Hypoxia-Inducible Factors
T2 - Master Regulators of Cancer Progression
AU - Schito, Luana
AU - Semenza, Gregg L.
N1 - Funding Information:
The authors regret that many important older papers were not cited due to journal policy. G.L.S. is an American Cancer Society Research Professor and the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine; cancer research in his lab is supported by grants from the American Cancer Society , Cindy Rosencrans Fund for Triple-Negative Breast Cancer , and Department of Defense Breast Cancer Research Program .
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Intratumoral hypoxia (reduced O2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial–mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.
AB - Intratumoral hypoxia (reduced O2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial–mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.
KW - oxygen biology
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85004065577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004065577&partnerID=8YFLogxK
U2 - 10.1016/j.trecan.2016.10.016
DO - 10.1016/j.trecan.2016.10.016
M3 - Review article
C2 - 28741521
AN - SCOPUS:85004065577
SN - 2405-8033
VL - 2
SP - 758
EP - 770
JO - Trends in Cancer
JF - Trends in Cancer
IS - 12
ER -